triapine + cisplatin

Triapine + cisplatin is an investigational **combination therapy** comprising **triapine**, a small molecule ribonucleotide reductase (RNR) inhibitor, and **cisplatin**, a platinum-based DNA-damaging cytotoxic agent. Triapine inhibits RNR, depleting deoxyribonucleotide pools essential for DNA replication and repair, while cisplatin forms DNA adducts that trigger cancer cell apoptosis. This combination is being explored primarily in the treatment of advanced, refractory **solid tumors** and particularly **gynecologic malignancies** (e.g., advanced-stage uterine cervix or vaginal cancers, platinum-resistant ovarian cancer), based on rationale that triapine potentiates cisplatin cytotoxicity by hindering DNA damage repair pathways. Mechanistic studies suggest sequence and timing of administration critically impact synergy.

Brand names

Platinol (for cisplatin)

Other names

triapinecisplatin